ADMA Biologics

ADMA

Market cap $4.01B

RAMSEY, N.J. and BOCA RATON, Fla.

ADMA posts 18% Q4 revenue growth as Asceniv drives record 2025 sales, with 2026 revenues seen topping $635M and margins set to expand.

ADMA Biologics, Inc. (ADMA) Q4 2025 Earnings Call Transcript

FY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year Growth FY 2025 ASCENIV Revenue Grew to $363 Million, Representing 51% Year-Over-Year Growth FY 2025 Adjusted Net Income( 1) of $161 Million, Representing 35% Year-Over-Year Growth FY 2025 Adjusted EBITDA( 2) of $231 Million, Representing 40% Year-Over-Year Growth Incoming CFO Appointment Expected to Further Enhance Financial Strategy, Working Capital Execution and Capital Allocation Discipline Advancing SG-001 Pipeline Program with Anticipated FDA Pre-IND Meeting in 2026; Potential Accelerated Path to Registrational Trial Ongoing Share Repurchases and Capital Structure to Increase Stockholder Value Reiterating Previously Provided 2026-2029 Financial Guidance RAMSEY, N.J. and BOCA RATON, Fla.

Adma Biologics (ADMA) closed the most recent trading day at $16.32, moving +2.06% from the previous trading session.

RAMSEY, N.J. and BOCA RATON, Fla.

Adma Biologics (ADMA) closed at $15.59 in the latest trading session, marking a -4.24% move from the prior day.

In the closing of the recent trading day, Adma Biologics (ADMA) stood at $17.5, denoting a +1.16% move from the preceding trading day.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

ADMA shares rose 13.8% over three months as demand for Asceniv surged, driving higher 2026 revenues and EBITDA targets amid margin expansion.